Trevogrumab halves lean-mass loss on semaglutide in mid-stage obesity trial

The wire

1. 01In a roughly 1,000-patient mid-stage trial presented at EASD in Milan, semaglutide alone cost 6.7% of lean mass at 26 weeks versus 3.3% with 75 mg trevogrumab; 25 mg gave 4.7% loss.
2. 02Muscle loss during incretin therapy is a live clinical question; MRI thigh measurement showed 75 mg preserved over 70% of lean mass loss at 52 weeks versus semaglutide alone.
3. 03Two deaths occurred on higher-dose trevogrumab plus garetosmab, one cardiac arrest and one undetermined; Regeneron says trevogrumab alone matched semaglutide's safety profile and dropped the triple combination.

From the source

Regeneron weight-loss drug halves muscle loss with Novo's semaglutide

Regeneron’s experimental anti-myostatin drug trevogrumab combined with Novo Nordisk’s semaglutide cut muscle loss by 50% in an obesity trial, with 75 mg preserving over 70% of lean mass at 52 weeks